Linden Thomas Advisory Services LLC Boosts Holdings in Edwards Lifesciences Co. (NYSE:EW)

Linden Thomas Advisory Services LLC raised its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 8.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,015 shares of the medical research company’s stock after acquiring an additional 527 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in Edwards Lifesciences were worth $535,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of EW. Martin Capital Advisors LLP boosted its position in shares of Edwards Lifesciences by 0.5% in the fourth quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock worth $1,944,000 after acquiring an additional 128 shares during the last quarter. Legacy Wealth Asset Management LLC boosted its position in shares of Edwards Lifesciences by 0.8% in the fourth quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock worth $1,293,000 after acquiring an additional 134 shares during the last quarter. DMC Group LLC boosted its position in shares of Edwards Lifesciences by 4.5% in the fourth quarter. DMC Group LLC now owns 3,561 shares of the medical research company’s stock worth $272,000 after acquiring an additional 154 shares during the last quarter. Granite Harbor Advisors Inc. boosted its position in shares of Edwards Lifesciences by 4.2% in the third quarter. Granite Harbor Advisors Inc. now owns 3,832 shares of the medical research company’s stock worth $265,000 after acquiring an additional 155 shares during the last quarter. Finally, Stableford Capital II LLC boosted its position in shares of Edwards Lifesciences by 2.7% in the fourth quarter. Stableford Capital II LLC now owns 5,980 shares of the medical research company’s stock worth $449,000 after acquiring an additional 155 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on EW shares. Mizuho lifted their price target on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. Wells Fargo & Company upgraded shares of Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 price objective on the stock in a research note on Friday, February 2nd. OTR Global upgraded shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Finally, Morgan Stanley lifted their price objective on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday, March 21st. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $91.73.

Insider Activity

In other news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, VP Catherine M. Szyman sold 27,000 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the transaction, the vice president now owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Over the last quarter, insiders sold 194,004 shares of company stock valued at $17,166,254. 1.29% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock opened at $88.01 on Friday. The company has a market cap of $52.98 billion, a PE ratio of 38.27, a P/E/G ratio of 4.39 and a beta of 1.05. The company has a fifty day moving average price of $90.27 and a two-hundred day moving average price of $78.76. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.38 and a quick ratio of 2.40. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. Research analysts expect that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.